Roberto Carillo
Family · Las Vegas, NVNPI 1790916575
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations.
Across 157 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$313
- AstraZeneca$287
- Bayer$281
- GSK$256
- Amgen$250
- AbbVie$215
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $313 |
| AstraZeneca | 13 | $287 |
| Bayer | 14 | $281 |
| GSK | 12 | $256 |
| Amgen | 12 | $250 |
| AbbVie | 11 | $215 |
| Astellas Pharma US Inc | 7 | $152 |
| Radius Health, Inc. | 7 | $142 |
| Boehringer Ingelheim | 5 | $93 |
| Pfizer | 5 | $88 |
| Lilly USA, LLC | 5 | $87 |
| Abbott | 3 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $64 |
| Boston Scientific | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 3 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $53 |
| Exact Sciences | 3 | $50 |
| Dexcom, Inc. | 3 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Optinose US, Inc. | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Lundbeck LLC | 1 | $27 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Merz North America, Inc. | 1 | $23 |
| Intra-sana Laboratories | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Mannkind Corporation | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Novartis | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Genentech USA, Inc. | 2 | $10 |
How this compares
$3,020 in reported general payments places this provider in the 85th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $371 |
| Alprazolam | 51 | $277 |
| Zolpidem Tartrate | 23 | $215 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $201 |
| Lorazepam | 13 | $165 |
Paid to pharmacies, not to this prescriber.
Other family in Las Vegas
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Kelly PapeshLas Vegas$28K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.